Article Information
History
- January 14, 2020.
Article Versions
- Version 1 (January 13, 2020 - 07:00).
- You are viewing Version 2, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- David Baker, PhD1,*,
- Gareth Pryce, PhD1,
- Louisa K. James, PhD1,
- Monica Marta, PhD1,2 and
- Klaus Schmierer, PhD1,2
- 1Blizard Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London E1 2AT, United Kingdom
- 2Clinical Board:Medicine (Neuroscience), The Royal London Hospital, Barts Health NHS Trust, London E1 1BB, United Kingdom
- ↵*Corresponding author:
Prof. David Baker; BartsMS, Blizard Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, 4 Newark Street, London E1 2AT. Tel: +442078822485; Fax: +442078822180; Email: david.baker{at}qmul.ac.uk
Posted January 14, 2020.
The ocrelizumab phase II extension trial suggests the potential to improve the risk:benefit balance in multiple sclerosis
